Table 2.
Baseline characteristics of the overall and propensity score-matched gastric cancer patient cohorts
| Characteristics |
Before matching (n = 869)
|
After matching (n = 528)
|
||||
|---|---|---|---|---|---|---|
| Patients without CVMD (n = 571) | Patients with CVMD (n = 298) | P value | Patients without CVMD (n = 264) | Patients with CVMD (n = 264) | P value | |
| Sex | 0.064 | 0.768 | ||||
| Male | 439 (76.9) | 212 (71.1) | 195 (73.9) | 192 (72.7) | ||
| Female | 132 (23.1) | 86 (28.9) | 69 (26.1) | 72 (27.3) | ||
| Age | < 0.001 | 0.073 | ||||
| ≤ 60 years | 298 (52.2) | 73 (24.5) | 83 (31.4) | 73 (27.7) | ||
| 61–74 years | 222 (38.9) | 177 (59.4) | 137 (51.9) | 161 (61.0) | ||
| ≥ 75 years | 51 (8.9) | 48 (16.1) | 44 (16.7) | 30 (11.3) | ||
| Smoking history | 0.55 | 0.719 | ||||
| No | 370 (64.8) | 187 (62.8) | 168 (63.6) | 164 (62.1) | ||
| Yes | 201 (35.2) | 111 (37.2) | 96 (36.4) | 100 (37.9) | ||
| Drinking history | 0.391 | 0.727 | ||||
| No | 486 (85.1) | 247 (82.9) | 218 (82.6) | 221 (83.7) | ||
| Yes | 85 (14.9) | 51 (17.1) | 46 (17.4) | 43 (16.3) | ||
| Family history of tumor | 0.537 | 0.349 | ||||
| No | 426 (74.6) | 228 (76.5) | 209 (79.2) | 200 (75.8) | ||
| Yes | 145 (25.4) | 70 (23.5) | 55 (20.8) | 64 (24.2) | ||
| Recurrence during follow-up | 0.414 | 0.452 | ||||
| No | 528 (92.5) | 280 (94.0) | 251 (95.1) | 247 (93.6) | ||
| Yes | 43 (7.5) | 18 (6.0) | 13 (4.9) | 17 (6.4) | ||
| Lymph node metastasis | < 0.001 | 0.725 | ||||
| No | 258 (45.2) | 183 (61.4) | 150 (56.8) | 154 (58.3) | ||
| Yes | 313 (54.8) | 115 (38.6) | 114 (43.2) | 110 (41.7) | ||
| Distant metastasis | 0.44 | 0.559 | ||||
| No | 557 (97.5) | 288 (96.6) | 259 (98.1) | 257 (97.3) | ||
| Yes | 14 (2.5) | 10 (3.4) | 5 (1.9) | 7 (2.7) | ||
| Tumor stage | 0.279 | 0.233 | ||||
| I | 120 (21) | 72 (24.1) | 56 (21.2) | 65 (24.6) | ||
| II | 230 (40.2) | 101 (33.9) | 118 (44.7) | 95 (36.0) | ||
| III | 207 (36.3) | 115 (38.6) | 85 (32.2) | 97 (36.7) | ||
| IV | 14 (2.5) | 10 (3.4) | 5 (1.9) | 7 (2.7) | ||
| Tumor differentiation | < 0.001 | 0.838 | ||||
| Well differentiated | 66 (11.6) | 53 (17.8) | 45 (17.1) | 40 (15.1) | ||
| Moderately differentiated | 267 (46.8) | 178 (59.7) | 154 (58.3) | 157 (59.5) | ||
| Poorly differentiated | 238 (41.6) | 67 (22.5) | 65 (24.6) | 67 (25.4) | ||
| Treatment regimen | 0.005 | 0.302 | ||||
| Without chemo-radiotherapy | 466 (81.6) | 219 (73.5) | 208 (78.8) | 198 (75.0) | ||
| With chemo-radiotherapy | 105 (18.4) | 79 (26.5) | 56 (21.2) | 66 (25.0) |
Data are presented as n (%). CVMDs: cardiovascular and metabolic diseases.